Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 11Active not recruiting 7Recruiting 5Terminated 3Withdrawn 1Unknown 1

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 2Breast 2Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 28Carcinoma, Non-Small-Cell Lung 22Lung Neoplasms 17Cholangiocarcinoma 13Biliary Tract Neoplasms 13Small Cell Lung Carcinoma 12Triple Negative Breast Neoplasms 8Breast Neoplasms 8Neoplasms 6Neoplasm Metastasis 5Liver Neoplasms 5Urinary Bladder Neoplasms 4Stomach Neoplasms 4Pancreatic Neoplasms 4Carcinoma 4Non-Muscle Invasive Bladder Neoplasms 3Gallbladder Neoplasms 3Colorectal Neoplasms 3Adenocarcinoma Of Esophagus 3Pathologic Complete Response 2Ovarian Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Bile Duct Neoplasms 2Advanced Biliary Tract Cancer 2Adenocarcinoma of Lung 2Adenocarcinoma 2Vaccinia 1SCLC, Limited Stage 1Resectable Intrahepatic Cholangiocarcinoma 1

Interventions

pembrolizumab 47Specimen Handling 29Magnetic Resonance Spectroscopy 25Biopsy 25Radiosurgery 17Gemcitabine 17Nivolumab 15Paclitaxel 14Cyclophosphamide 13Cisplatin 13Carboplatin 13Bevacizumab 12Drug Therapy 11Taxes 10Radiotherapy 10Oxaliplatin 10Leucovorin 10Irinotecan 10Fluorouracil 10Capecitabine 10trastuzumab deruxtecan 8fludarabine 8Pemetrexed 8Doxorubicin 8Cetuximab 8cemiplimab 7abemaciclib 7Trastuzumab 7Fulvestrant 7Docetaxel 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Neoplasm Metastasis × durvalumab × Clear all
NCT03907475 2026-05-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
115 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT06103864 2026-04-30

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

AstraZeneca

Phase 3 Recruiting
625 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04900818 2026-03-05

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

I-Mab Biopharma US Limited

Phase 1 Recruiting
330 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Biliary Tract Neoplasms, Neoplasm Metastasis, Stomach Neoplasms

NCT02029001 2025-08-07

MOST plus

Centre Leon Berard

Phase 2 Recruiting
900 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT06508216 2024-07-22

COMPASS-TNBC

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
50 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡